GlassScriptPhysician profile
Ryan A Mccoy
NPI 1811998263
$1,493.23
in general payments reported to CMS, 2019-2025
23 companies · $236 in 2025
The $236 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $188 · 2021: $221 · 2022: $110 · 2023: $282 · 2024: $232 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $211.13 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Tris Pharma INC | $160.97 | 2019-2021 | |
| Sobi, INC | $148.46 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.23 | 2020-2021 | |
| Sanofi Pasteur INC. | $106.58 | 2021-2024 | |
| Verrica Pharmaceuticals INC. | $102.86 | 2024-2025 | Ycanth |
| Kaleo, INC. | $76.76 | 2019-2023 | Auvi-Q |
| Seqirus USA INC | $62.04 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $56.04 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $50.66 | 2024-2025 | |
| Adlon Therapeutics L.P. | $46.66 | 2020-2021 | |
| Pfizer INC. | $45.96 | 2023-2024 | |
| Cranial Technologies, INC | $44.38 | 2019-2023 | Doc Band |
| Glaxosmithkline, LLC. | $42.31 | 2019-2021 | |
| Neos Therapeutics, LP | $40.80 | 2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $37.83 | 2019 | |
| Shire North American Group INC | $32.03 | 2019 | |
| Alexion Pharmaceuticals, INC. | $28.71 | 2023 | Strensiq |
| Amneal Pharmaceuticals LLC | $21.83 | 2019 | |
| Abbvie INC. | $18.25 | 2025 | |
| Rhodes Pharmaceuticals L.P. | $16.46 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $15.64 | 2020 | |
| Lnhc, INC | $14.64 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.